Table 1. Summary of presented/published clinical trials of ranibizumab standard monthly and variable dosing regimens for exudative age-related macular degeneration. † Theoretical mean number ...

Neovascular AMD is an advanced form of the condition, also known as “exudative AMD" or “wet macular degeneration.” The wet ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming ...

Designed for people experiencing macular degeneration—the leading cause of vision loss among people over the age of 60—the glasses mimic insect eyes, which use anywhere from dozens to ...

This article evaluates the currently used treatment regimens in ocular anti-VEGF therapy for exudative age-related macular degeneration. Anti-VEGF therapies using variable injection regimens and ...